Abivax Announces Presentation Of Late-Breaking Abstract For Obefazimod From Abtect Phase 3 Induction Trials At 2025 UEG Meeting
Refinitiv閱讀少於1分鐘
Abivax SA ABVX:
ABIVAX ANNOUNCES PRESENTATION OF LATE-BREAKING ABSTRACT FOR OBEFAZIMOD FROM THE ABTECT PHASE 3 INDUCTION TRIALS AT 2025 UNITED EUROPEAN GASTROENTEROLOGY (UEG) MEETING
登入或建立一個永久免費帳戶來閱讀此新聞